The 2023 Chinese Medical Association Annual Conference on Organ Transplantation (CSOT) concluded successfully

The "2023 Chinese Medical Association Organ Transplantation Annual Conference" sponsored by the Chinese Medical Association and the Organ Transplantation Branch of the Chinese Medical Association and hosted by the First Affiliated Hospital of Xi'an Jiaotong University opened grandly on the morning of September 25, 2023 in Xi'an, the ancient capital of thirteen dynasties and the starting point of the Silk Road. Nearly 2,000 experts and medical workers from domestic and foreign fields related to organ transplantation gathered at the shore of Bashui for the grand event.

Relevant colleagues from the Medical Department and Marketing Department of AlloDx attended this meeting and showcased the company's latest products and technologies in the field of organ transplantation diagnosis, especially the latest clinical application data of the Ankang non-invasive test (AlloK seq®), attracting a large number of experts, scholars and industry insiders to come and communicate.

During the meeting, academic reports by multiple experts demonstrated the clinical application data of AlloK seq®, which resonated with the audience.

my country's organ transplantation field has achieved today's achievements and demonstrated extraordinary influence in the world. It relies on the hard work of transplantation experts and their continuous climb to the peak of transplantation medicine. In the future, AlloDx looks forward to sincere cooperation and common development with more colleagues to provide more and better products and services in the field of transplantation medicine.

About AlloDx
AlloDx was founded in 2018, focuses on next-generation molecular diagnostic technology R&D and clinical translation in organ transplantation, and is a national high-tech enterprise and a Ministry of Science and Technology technology-based SME, honored with Shanghai's 2021 SME Innovation Fund support, among others. To date, it holds 15 core invention patents and 23 software copyrights, has published 18 dd-cfDNA-related articles (14 SCI), and 6 cooperative research results have been invited as oral presentations at international transplant congresses. It has completed testing of over 7,000 dd-cfDNA samples and accumulated a substantial 'China Organ Transplant dd-cfDNA Gene Database.'